Document Detail


Therapeutic potential of S179D prolactin--from prostate cancer to angioproliferative disorders: the first selective prolactin receptor modulator.
MedLine Citation:
PMID:  16989600     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Increasing evidence suggests an important role for autocrine/paracrine prolactin in breast and prostate cancers and other disease states. Prolactin production in these extrapituitary sites is not governed by dopamine agonists, a finding that has spurred the production of prolactin receptor antagonists. This review focuses on one such antagonist, S179D prolactin, which was produced by mimicking a natural antagonist, phosphorylated prolactin. S179D prolactin is a very effective growth antagonist, partly because it inhibits signalling from unmodified prolactin and partly because it produces its own intracellular signal. This signal results in cell differentiation, cell-cycle arrest or apoptosis depending on dose, duration of treatment and cellular context. S179D prolactin is also a potent antiangiogenic and initial studies have shown it to be a potent anti-inflammatory agent. In light of these additional modes of action, it is suggested that S179D prolactin should now be more aptly referred to as a selective prolactin receptor modulator.
Authors:
Ameae M Walker
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  15     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-22     Completed Date:  2006-11-30     Revised Date:  2014-11-10    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1257-67     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Humans
Male
Neovascularization, Pathologic / drug therapy*,  metabolism
Prolactin / pharmacology,  therapeutic use*
Prostatic Neoplasms / drug therapy*,  metabolism*,  pathology
Receptors, Prolactin / antagonists & inhibitors,  metabolism*
Grant Support
ID/Acronym/Agency:
NIDDK 61005//PHS HHS; R01 DK061005/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Prolactin; 0/prolactin, Asp(179)-; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Integrin antagonists as therapeutics for inflammatory diseases.
Next Document:  Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension.